ASP Isotopes Surges 30% on Record Silicon-28 Supply Deal
Landmark quantum computing supply agreement and a strategic U.S. acquisition fuel major rally in the company's shares.
Shares of ASP Isotopes Inc. (NASDAQ: ASPI) soared over 30% on Monday following a significant business update that included the company's largest-ever supply agreement for enriched silicon-28 and a strategic acquisition in the United States.
The dual announcements sent the stock climbing, highlighting growing investor confidence in the company's role as a critical supplier for the burgeoning quantum computing and next-generation semiconductor industries. The company confirmed it had for its high-purity silicon-28 with a U.S.-based client, with deliveries scheduled for the first quarter of 2026.
Enriched silicon-28 is a highly sought-after material essential for the advancement of . By providing a 'spin-free' environment, it helps protect quantum bits (qubits) from decoherence, a major hurdle in developing stable and powerful quantum processors. This order, as noted by the company, confirms the growing market acceptance of its Electronic Gases business as it aims to become a leading global supplier.
Further fueling the rally, ASP Isotopes announced a strategic move to expand its radiopharmaceutical business. The company , marking the entry of its subsidiary, PET Labs Pharmaceuticals, into the lucrative U.S. market. This acquisition is expected to be immediately accretive and contribute positively to revenues, EBITDA, and earnings per share in 2026 as the company builds out an integrated radiopharmacy platform.
Following the news, ASP Isotopes' stock was trading up 30.9% at $13.28. The significant catalysts underscore the company's progress in commercializing its proprietary enrichment technology across multiple high-growth sectors, positioning it at the forefront of both advanced computing and medical diagnostics.